Seattle Genetics Inc.

(SGEN) Trade

By |

Profile

Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other oncology programs in pivotal trials, including enfortumab vedotin for bladder cancer. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Contact Information

Website: www.seattlegenetics.com
Email: investors@seagen.com
Main Phone: +1 425 527-4000
Address: 21823 - 30th Drive South East
Address 2: Building 3
State: WA
City / Town: Bothell
Country: USA
Postal Code: 98021

Issuer Information

Exchange: NGS
CEO: Clay B. Siegall
Employees: 1302
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More

Profile

Seattle Genetics is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. The company has several other oncology programs in pivotal trials, including enfortumab vedotin for bladder cancer. Seattle Genetics also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Contact Information

Website: www.seattlegenetics.com
Email: investors@seagen.com
Main Phone: +1 425 527-4000
Address: 21823 - 30th Drive South East
Address 2: Building 3
State: WA
City / Town: Bothell
Country: USA
Postal Code: 98021

Issuer Information

Exchange: NGS
CEO: Clay B. Siegall
Employees: 1302
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

View More
$ 113.98 $ -0.15 (-0.13%)
Last Price 113.98 Change $ -0.15 Change % -0.13 Tick N/A
Bid 113.10 Bid Size 200.00 Ask 114.95 Ask Size 200.00
Open 114.00 High 114.67 Low 113.05 Prev Close 114.13
Last Trade Volume 1.4 mi 52 Wk Hi 122.36 52 Wk Low 51.50
Market Cap 19.5 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 171,385,656.00 EPS (TTM) -1.87 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 52 170
Number of Buys 41 106
Number of Sells 11 64
Net Activity 1537290 5601762
Last 10 Buys Shares
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Last 10 Sell Shares
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Vaughn B. Himes 1,000
Vaughn B. Himes 1,000
Vaughn B. Himes 1,000
Darren S. Cline 1,000
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Clay B. Siegall 1,000
Darren S. Cline 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 77 77 77 80
Low Target Price Estimate 50 50 50 50
Mean Target Price Estimate 64.82 64.64 64.64 66.64
Standard Deviation 9.23 9.31 9.31 10.11
Date of Most Recent Estimate 06/04/18 05/17/18 05/17/18 06/11/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 5 5 6
Moderate Buy 2 2 3 3
Hold 5 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.92 2.08 2.04 1.97